Biodexa Pharmaceuticals Plc

NasdaqCM:BDRX Stok Raporu

Piyasa değeri: US$3.4m

Biodexa Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Biodexa Pharmaceuticals has a total shareholder equity of £8.7M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £14.0M and £5.2M respectively.

Anahtar bilgiler

0%

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranın/a
NakitUK£5.06m
EşitlikUK£8.73m
Toplam yükümlülüklerUK£5.24m
Toplam varlıklarUK£13.97m

Son finansal sağlık güncellemeleri

Recent updates

Midatech Pharma regains compliance with Nasdaq's minimum bid price requirement

Oct 18

Midatech Pharma reports 1H results

Sep 14

Midatech surges on the promise of drug delivery system

Jun 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BDRX's short term assets (£7.5M) exceed its short term liabilities (£3.5M).

Uzun Vadeli Yükümlülükler: BDRX's short term assets (£7.5M) exceed its long term liabilities (£1.8M).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BDRX is debt free.

Borcun Azaltılması: BDRX has no debt compared to 5 years ago when its debt to equity ratio was 4.4%.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BDRX has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Tahmini Nakit Akışı: BDRX is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.


Sağlıklı şirketleri keşfedin